Alma Lasers
Last updated: Jul 31, 2026
Alma Lasers is an Israeli medical-device company whose Alma brand develops and sells laser, light, radiofrequency, plasma, ultrasound, and shockwave systems for medical aesthetics, dermatology, beauty, and selected surgical indications. It is a mature, wholly owned operating subsidiary of Sisram Medical, the Hong Kong-listed medical-aesthetics group majority-owned by Fosun Pharma.
Visit WebsiteCompany Overview
Alma Lasers develops and commercializes energy-based medical devices rather than a single therapeutic product. Its official portfolio spans laser and light sources, radiofrequency, plasma, ultrasound, imaging and analysis, and focused low-intensity extracorporeal shockwave technology. Examples include Alma Hybrid for configurable ablative and non-ablative resurfacing, Soprano platforms using diode lasers and Alma's SHR delivery approach for hair removal, PrimeX for radiofrequency and ultrasound body treatments, Harmony multi-application platforms, and Alma Duo for sexual-wellness shockwave treatment. The economic offering is therefore a combination of consoles, handpieces, energy-control systems, treatment protocols, training, clinical support, and service.
The commercial model targets physicians, dermatology practices, aesthetic clinics, surgical practices, and beauty operators that want multiple indications from a manageable equipment base. Skin rejuvenation, resurfacing, pigmentation and vascular lesion treatment, acne and scar treatment, hair removal, body contouring, skin tightening, and selected sexual-health or surgical procedures give a platform and its distributor network several routes to clinic adoption. Alma's current website reports more than 25 years of history, more than 50 patents, 12 direct channels, more than 100 distributors, more than 230 publications, and eight academies. These are company-reported figures, not independently audited traction metrics, but they are consistent with a substantial commercial, education, and clinical-support infrastructure.
Alma competes with Candela, Cynosure, Lumenis, Cutera, Fotona, BTL, and lower-cost regional suppliers, while clinics can also substitute single-indication devices or non-device treatments. Defensibility is consequently mixed. Multi-modality platforms, clinical evidence, regulatory clearances, practitioner familiarity, cooling and treatment-control features, installed-base service, and channel reach can support adoption and cross-selling. They do not remove price pressure, procedure commoditization, operator-dependence, or the requirement to support indication-specific safety and efficacy claims. Recent platform launches, awards, and education events are commercialization signals, but they are not evidence of independently verified market share, margins, or recurring revenue.
Ownership materially changes the diligence frame. Sisram's official materials describe Alma Lasers Ltd. as a wholly owned subsidiary, say Sisram was established after Fosun Pharma's acquisition of Alma, and report a group presence in more than 110 countries and regions. Alma is therefore best analyzed as a scaled corporate operating asset with ongoing R&D, manufacturing, sales, and distribution responsibilities, not as a venture-backed independent startup. The relevant questions are product-level growth, geographic and channel economics, regulatory and post-market performance, service quality, manufacturing concentration, and how much value Alma contributes within Sisram's broader ecosystem. Public materials establish the ownership and operating relationship, but do not provide a clean standalone Alma valuation or full standalone financial view.
Defense and national-security relevance is limited and indirect. Compact energy delivery, tissue-heating control, imaging, and clinical workflows could be studied for military medicine, rehabilitation, expeditionary dermatology, or field clinics, but those are hypothetical applications requiring different procurement, durability, training, and evidence standards. The public evidence reviewed does not establish defense contracts, military deployments, battlefield-care validation, or a security-focused roadmap. Alma should remain a commercial medical-aesthetics reference with weak dual-use adjacency, not a defense technology opportunity.
Strategic Fit Assessment
Alma has meaningful technology, clinical, channel, and brand assets, but it is not an independent startup or a conventional venture-financing target. The 2013 Fosun acquisition and its integration into Sisram Medical make ownership, segment reporting, and corporate portfolio priorities more relevant than startup funding or standalone exit analysis. It is useful for strategic benchmarking and market diligence, not as a live internal priority signal.
Strategic Value to U.S.-Israel Alliance
Strategic value lies in a scaled Israeli-origin energy-based-device platform with broad modality coverage, practitioner education, regulatory know-how, manufacturing capability, and a global direct-and-distributor network. Alma can serve as a benchmark for commercialization, clinical evidence, and clinic workflow integration. Its value to a dual-use thesis is constrained because the public business is overwhelmingly oriented toward elective aesthetics and outpatient medicine, while control already sits within the Sisram/Fosun corporate structure.
Key Technologies
- Ablative and non-ablative fractional laser systems
- Multi-wavelength diode laser and SHR hair-removal delivery
- Intense pulsed light and Q-switched laser platforms
- Radiofrequency energy delivery for tissue remodeling and body contouring
- Ultrasound-based aesthetic treatment systems
- Focused low-intensity extracorporeal shockwave therapy
- Integrated epidermal cooling, treatment-control, and multi-handpiece workflows
Use Cases & Applications
- Laser hair removal across varied skin and hair types
- Skin rejuvenation, resurfacing, acne, and scar treatment
- Pigmented and vascular lesion treatment
- Body contouring, cellulite reduction, and skin tightening
- Office-based dermatology and aesthetic procedures
- Selected surgical, gynecological, and feminine-health procedures
- Sexual-wellness shockwave treatment
- Potential but unvalidated expeditionary dermatology or military-medicine use
Sources and verification
This profile is based on public-source research, Claw & Talon curation, and editorial judgment. Inclusion does not imply endorsement, partnership, investment, or a recommendation to transact. Readers should still confirm current status, customers, funding, and product claims before relying on this profile. The editorial policy explains how profiles are researched, where automated drafting is used, and how corrections work.
This record lists 9 public references used for company identity, status, positioning, or material-claim review.
Public sources
The links below are visible public references used for source discipline around company identity, status, funding, customer, acquisition, public-company, or other material claims where available.
- almalasers.com Public source used for profile verification.
- almalasers.com Public source used for profile verification.
- almalasers.com Public source used for profile verification.
- almalasers.com Public source used for profile verification.
- sisram-medical.com Public source used for profile verification.
- sisram-medical.com Public source used for profile verification.
- sisram-medical.com Public source used for profile verification.
- sisram-medical.com Public source used for profile verification.
- almalasers.com Public source used for profile verification.
- Profile update timestamp Last updated in the Claw & Talon database on Jul 31, 2026.
Investor Lens
What this entry is
Acquired asset
Why it may matter
Alma Lasers may matter as a Health & BioTech entry with not currently an investable standalone company for Israeli technology research.
How an independent investor should read this
Not currently an investable standalone company. Read this profile as a starting point for independent verification, not as a recommendation or suitability assessment.
Evidence to verify
- Verify current status
- Verify technical claims
Main investor questions
- Is this entry a benchmark, buyer, ecosystem node, acquired asset, or strategic reference rather than a live startup opportunity?
- What does this reference clarify about buyers, sector structure, public-market context, or strategic demand?
- What evidence would change the thesis or show that the profile is stale?
What not to infer
- Inclusion does not imply endorsement.
- Inclusion does not imply allocation availability or current fundraising.
- Scores do not indicate investment suitability or expected returns.
- Strategic importance does not automatically imply venture return potential.
Diligence questions
- What evidence verifies Alma Lasers's current customer traction, deployment status, and revenue concentration?
- Which technical claims are independently demonstrable today, and which remain roadmap or pilot-stage assertions?
- Is there a credible national-security or public-sector use case, or is the company primarily a commercial technology asset?
- What regulatory, procurement, and buyer-adoption constraints could slow deployment in strategic or government-adjacent markets?
- Is the company a live venture opportunity, a mature strategic reference, an acquired asset, or primarily a market-mapping entry?
Related sector
See the Health & BioTech sector page for market context, related subcategories, and other Israeli companies in this part of the database.
Related companies
Need a diligence readout?
Use the profile and related checklists as a starting point. If the decision needs more context, request a company screen, founder-call prep, diligence memo, or sector readout.